Applications Vaccixcell

Influenza Virus Type A (H7N9)

Description

H7N9 is a virus that generally affects birds but is known to infect humans. Most cases of H7N9 epidemic occurred in China, with the country having experienced its 5th epidemic to date. Mortality rate for H7N9 is around 40%.

Prevention

There is no existing vaccine for H7N9 though there are several vaccine candidates that are undergoing clinical trials.

Vaccine Production

H7N9 can be cultured in-vitro through propagation in mammalian cell lines. VacciXcell's tidemotion bioreactor is the best truly linearly scalable bioreactor currently available in the market for culturing adherent mammalian cell lines. Using this technology, it is easier to scale up and achieve production scale for vaccine production.

To learn more about Tidemotion Bioreactors click here